These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 26555014)
1. Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds. Tai CJ; Li CL; Tai CJ; Wang CK; Lin LT J Vis Exp; 2015 Oct; (105):e53124. PubMed ID: 26555014 [TBL] [Abstract][Full Text] [Related]
2. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry. Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176 [TBL] [Abstract][Full Text] [Related]
3. Limonium sinense and gallic acid suppress hepatitis C virus infection by blocking early viral entry. Hsu WC; Chang SP; Lin LC; Li CL; Richardson CD; Lin CC; Lin LT Antiviral Res; 2015 Jun; 118():139-47. PubMed ID: 25865056 [TBL] [Abstract][Full Text] [Related]
4. Strategies for antiviral screening targeting early steps of virus infection. Peng T Virol Sin; 2010 Aug; 25(4):281-93. PubMed ID: 20960301 [TBL] [Abstract][Full Text] [Related]
5. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry. Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204 [TBL] [Abstract][Full Text] [Related]
6. (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry. Chung CY; Liu CH; Wang GH; Jassey A; Li CL; Chen L; Yen MH; Lin CC; Lin LT Sci Rep; 2016 Jul; 6():29969. PubMed ID: 27426693 [TBL] [Abstract][Full Text] [Related]
7. Screening of small-molecule compounds as inhibitors of HCV entry. Yang JP; Zhou D; Wong-Staal F Methods Mol Biol; 2009; 510():295-304. PubMed ID: 19009270 [TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Gentzsch J; Hinkelmann B; Kaderali L; Irschik H; Jansen R; Sasse F; Frank R; Pietschmann T Antiviral Res; 2011 Feb; 89(2):136-48. PubMed ID: 21167208 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244 [TBL] [Abstract][Full Text] [Related]
11. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus. Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600 [TBL] [Abstract][Full Text] [Related]
12. Identification of a series of 1,3,4-trisubstituted pyrazoles as novel hepatitis C virus entry inhibitors. Hwang JY; Kim HY; Park DS; Choi J; Baek SM; Kim K; Kim S; Seong S; Choi I; Lee HG; Windisch MP; Lee J Bioorg Med Chem Lett; 2013 Dec; 23(23):6467-73. PubMed ID: 24125883 [TBL] [Abstract][Full Text] [Related]
13. (-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry. Calland N; Albecka A; Belouzard S; Wychowski C; Duverlie G; Descamps V; Hober D; Dubuisson J; Rouillé Y; Séron K Hepatology; 2012 Mar; 55(3):720-9. PubMed ID: 22105803 [TBL] [Abstract][Full Text] [Related]
14. Benzothiazepinecarboxamides: Novel hepatitis C virus inhibitors that interfere with viral entry and the generation of infectious virions. Kim HY; Kong S; Oh S; Yang J; Jo E; Ko Y; Kim SH; Hwang JY; Song R; Windisch MP Antiviral Res; 2016 May; 129():39-46. PubMed ID: 26850830 [TBL] [Abstract][Full Text] [Related]
15. Benzhydrylpiperazine compounds inhibit cholesterol-dependent cellular entry of hepatitis C virus. Chamoun-Emanuelli AM; Pécheur EI; Chen Z Antiviral Res; 2014 Sep; 109():141-8. PubMed ID: 25019406 [TBL] [Abstract][Full Text] [Related]
16. Entry inhibitors and future treatment of hepatitis C. Fofana I; Jilg N; Chung RT; Baumert TF Antiviral Res; 2014 Apr; 104():136-42. PubMed ID: 24525381 [TBL] [Abstract][Full Text] [Related]
18. Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16. Wang JY; Lin CJ; Liu CH; Lin LT J Vis Exp; 2019 Jul; (149):. PubMed ID: 31355786 [TBL] [Abstract][Full Text] [Related]
19. Micrococcin P1, a naturally occurring macrocyclic peptide inhibiting hepatitis C virus entry in a pan-genotypic manner. Lee M; Yang J; Park S; Jo E; Kim HY; Bae YS; Windisch MP Antiviral Res; 2016 Aug; 132():287-95. PubMed ID: 27387825 [TBL] [Abstract][Full Text] [Related]
20. Screening and Identification of Lassa Virus Entry Inhibitors from an FDA-Approved Drug Library. Wang P; Liu Y; Zhang G; Wang S; Guo J; Cao J; Jia X; Zhang L; Xiao G; Wang W J Virol; 2018 Aug; 92(16):. PubMed ID: 29899092 [No Abstract] [Full Text] [Related] [Next] [New Search]